An interventional study of Oxybutynin and medical device Urostim in Overactive Bladder (OAB), Transcutaneous Neurostimulation and Posterior Tibial Nerve Stimulation, sponsored by Centre Hospitalier Universitaire, Amiens. Recruiting at 1 site in France. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2025-11-18.
Sponsored by Centre Hospitalier Universitaire, Amiens · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Urinary Bladder, Overactive with a site in France — 6 open to participants now, 6 under way, none of them phase 3. Urinary Bladder, Overactive · France.
Among the 53 studies in Urinary Bladder, Overactive with a site in France, this one is the 27th largest by planned enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2025, is one of 11 with no phase, and was the 52nd registered.
861 studies on the registry are indexed under Urinary Bladder, Overactive; 128 are open to participants now.
Browse Urinary Bladder, Overactive studies →6 of the 53 studies in Urinary Bladder, Overactive with a site in France are open now. Recruiting first, the newest first:
DJO UK Ltd · Sites in France
Ages 18+
Stimuli Technology · Sites in France, Italy, United Kingdom
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–99
University Hospital, Lille · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 75 Urinary Bladder, Overactive studies recruiting now, 45 (60%) set no upper age limit and 16 (21%) stop at 75 or younger; 7 take children under 18; 8 take healthy volunteers.
This study: 6 Years to 16 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 124 is above the median of 70 across 652 interventional studies indexed under Urinary Bladder, Overactive.
Median enrollment 267 across the 40 interventional studies, 100 across the 13 observational. Of the 44 that completed or were terminated, 19 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 53 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire, Amiens is the lead sponsor of 586 studies on the registry; 185 are open to participants now.
Centre Hospitalier Universitaire, Amiens has 1 study filed under Urinary Bladder, Overactive — fewer than ten, so there is no comparison to draw.
2 of the studies in Urinary Bladder, Overactive with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05772637Assistance Publique - Hôpitaux de ParisClinical and Urodynamic Assessment of Bladder Sensation in Multiple Sclerosis | 2027-02-14 |
| NCT05949567Assistance Publique - Hôpitaux de ParisDoes Position Influence the Diagnosis of Detrusor Overactivity in a Neurological Population | 2027-04-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 53 studies in Urinary Bladder, Overactive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The absence of infectious, urological and neurological causes defines the idiopathic character of overactive bladder (OAB). Although a progressive approach starting with behavioural therapy (urotherapy) is recommended, anticholinergic agents remain the mainstay of medical treatment of overactive bladder (OAB) in children. Bladder neuromodulation is also used but no study with sufficient evidence has assessed its effectiveness and tolerance compared to the reference treatment. The purpose of HAV-O-TENS is to demonstrate the non-inferiority of treating idiopathic overactive bladder (OAB) in children using posterior tibial nerve stimulation (PTNS) compared to the reference treatment with oxybutynin after three months of treatment.
Before inclusion, patients will receive instructions for urotherapy and a treatment plan. After confirming the diagnosis and obtaining informed consent, patients will be randomly assigned to either oxybutynin or PTNS (posterior tibial nerve stimulation) treatment, and their effectiveness, tolerance, and adherence will be monitored.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Oxybutynin
Device: medical device Urostim
oxybutynin
medical device used to deliver posterior tibial nerve stimulation (PTNS)
Variation of DVISS score between PTNS treatment group and oxybutynin group
DVISS score is : Dysfunctional Voiding and Incontinence Symptoms Score (DVISS) Questionnaire. The DVISS is a 13-item instrument that includes 1 QOL question. The first 5 questions are scored using an ordinal scale with the remainder in binary format. The DVISS scores are based on the estimated odds ratio (OR) for each question between cases and controls. For example, a score of 1 is given if the item's OR is between 2 and 10, and a score of 5 is given if the OR is greater than 50. The total score can range from 0 to 35 with a cutoff score of 8.5 having 90% sensitivity and specificity at detecting BBD.
Time frame: at 3 months
variation of treatment duration between both groups
Time frame: at 6 months
variation of time to treatment efficacy between both groups
Time frame: at 6 months
variation of tolerance between both groups
Time frame: at 3 months
variation of tolerance between both groups
Time frame: at 6 months
variation of compliance between both groups
variation of compliance between both groups
Time frame: at 3 months
variation of compliance between both groups
variation of compliance between both groups
Time frame: at 6 months
variation of long-term efficacy between both groups
Time frame: at 12 months
variation of long-term efficacy between both groups
Time frame: at 18 months
variation of long-term efficacy of AOB frequency between both groups
Long term efficacy of OAB frequency is measured with DVISS score. The DVISS is a 13-item instrument that includes 1 QOL question. The first 5 questions are scored using an ordinal scale with the remainder in binary format. The DVISS scores are based on the estimated odds ratio (OR) for each question between cases and controls. For example, a score of 1 is given if the item's OR is between 2 and 10, and a score of 5 is given if the OR is greater than 50. The total score can range from 0 to 35 with a cutoff score of 8.5 having 90% sensitivity and specificity at detecting BBD.
Time frame: at 24 months
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Mar 2029, 40 months after the start.
Of 135 non-industry interventional studies with no phase under Urinary Bladder, Overactive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 40 months is above that.
Counting every sponsor, half of 176 studies reached it within 19 months; a quarter within 10 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire, Amiens →